NASDAQ · Biotechnology

EPRX (EPRX) Stock

$6.05 +4.13% NASDAQ: EPRX Healthcare

Valuation

MetricValue
Price$6.05
Market Cap$202.55M
P/E Ratio-5.99
P/B Ratio2.57
P/S Ratio0.00
EPS (TTM)$-1.05
52-Week High$9.32
52-Week Low$4.19
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-65.85%
ROA-62.79%
ROCE-67.50%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio14.17

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-18.0M$-28.0M$-39.0M$-54.0M
Net Profit$-18.0M$-18.0M$-28.0M$-37.0M$-54.0M
EPS$-1.61$-0.96$-1.17$-0.76$-1.05
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$31.0M$26.0M$20.0M$35.0M$86.0M
Total Liabilities$12.0M$16.0M$19.0M$3.0M$6.0M
Cash$21.0M$25.0M$19.0M$33.0M$81.0M
Borrowings$10.0M$12.0M$10.0M$0$0

Latest News

Eupraxia Pharmaceuticals Announces Executive Leadership Changes MT Newswires · Jul 13, 2026 Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth GlobeNewswire · Jul 13, 2026 Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization GlobeNewswire · Jul 7, 2026 Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders GlobeNewswire · Jun 19, 2026 Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-14.0M$-21.0M$-30.0M$-29.0M
Investing Cash Flow$-12.0M$10.0M$0$0$-1.0M
Financing Cash Flow$0$0$5.0M$0$0
Net Cash Flow$16.0M$6.0M$1.0M$14.0M$47.0M
Free Cash Flow$-12.0M$-15.0M$-21.0M$-30.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-14.42%
Quick Ratio19.30
Interest Coverage—
Return 1Y24.51%
Return 3Y—
Return 5Y—

Ownership

Insiders Held14.22%
Institutions Held41.96%
Institutions Float Held48.92%
Institutional HolderSharesReport Date
Beutel, Goodman & Company Ltd3,666,4652026-03-31
Affinity Asset Advisors, Llc1,589,0052026-03-31
Balyasny Asset Management LP1,350,0002026-03-31
Vivo Capital, LLC1,350,0002026-03-31
Scotia Capital Inc.1,342,1782026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $6.42 -4.04% -1.62 $140.50M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IVAInventiva S.A. $4.47 +1.59% -2.04 $232.36M 0.00%
MDWD $14.35 -1.85% -7.94 $184.34M 0.00%
NAUT $1.20 -27.71% -5.06 $152.49M 0.00%

About EPRX

EPRX is led by CEO James A. Helliwell, employs 33 people, headquartered in CA, publicly traded since 2024.

EPRX stock trades at $6.05 with a market capitalization of $202.55M. The stock is valued at a price-to-earnings (P/E) ratio of -5.99, price-to-book of 2.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.19 and $9.32, and currently trades 35.1% below its 52-week high.

On profitability, EPRX generates a return on equity (ROE) of -65.85%, return on capital employed of -67.50%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides